Dr. Elkashef is a psychiatrist with over 25 years experience in medication development, CNS biomarkers, brain imaging and translational medicine. He completed his residency training in psychiatry at the University of Maryland in 1990. He then joined NIMH, his research focus was on schizophrenia clinical trials, movement disorders and brain imaging. In 1997 he joined NIDA's medication development division as the chief of the clinical trials branch

Dr.Trist is a consultant and advisory board member for Neuropill. He retired in December 2008 as Vice President and Head of Strategy and Operations for the Psychiatry Center of Excellence for Drug Discovery within GlaxoSmithKline. Before that he was the Director of Pharmacology, with the focus on finding medicines for CNS diseases. Dr.Trist holds a degree in Biochemistry and a PhD in Pharmacology from the University College in London.

Dr. Daniel is a consultant and advisory board member for Neuropill. He is a psychiatrist and a world expert in schizophrenia research. He Joined NIMH in 1986 his research focus was on schizophrenia neuroimaging and clinical trials. He worked as the director of clinical trials at Stanley research foundation. He consults to numerous pharmaceutical companies on clinical trials design, assessments and medications development for schizophrenia.

Mr. Gaffney is a consultant and advisory board member for Neuropill. He is an attorney with more than 20 years' experience in the intersection of law and science. He has extensive expertise with intellectual property law. He advises pharmaceuticals, biotechnology, medical device and dietary supplement companies on matters involving the development, and manufacture of pharmaceuticals, biologic, medical devices, and dietary supplement products.